|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
4.11 Dép., diag. & prono. - Ovaire
|
|
|
|
Screening women for ovarian cancer shows first success [STAT]
|
|
|
|
|
|
The
women were randomly assigned to one of three groups: annual
transvaginal ultrasound, which tries to detect suspicious masses; an
annual blood test for CA-125 plus ultrasound; or no screening.At first
blush, it seemed that screening failed again...
|
|
|
|
|
|
|
Groundbreaking Trial Reports Positive Results on Screening for Ovarian Cancer [ACS]
|
|
|
|
|
|
Dr.
Ian Jacobs and colleagues studied approximately 200,000 women over more
than a decade to determine whether multi-modal screening (MMS) with a
“risk of ovarian cancer algorithm” (ROCA), a quantitative algorithm
based on age, risk status and CA-125 levels over time, was effective in
reducing ovarian cancer mortality compared with ultrasound alone or
usual care.
|
|
|
|
|
|
|
|
Early Detection of Ovarian Cancer May Become Possible [NY Times]
|
|
|
|
|
|
Her
reason for caution was that the study passed only two of three tests of
statistical significance, which means that the apparent benefits of
screening might have been due to chance. She said a few more years of
monitoring the participants would resolve that question.
|
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5.2 Pharma
|
|
|
Ariad Said to Name Panayiotopoulos CEO After Activist Push [Bloomberg Business]
|
|
|
|
|
|
Ariad
Pharmaceuticals Inc., a developer of blood and lung-cancer treatments,
is set to name Paris Panayiotopoulos as chief executive officer, people
familiar with the matter said. The move comes eight months after
activist investor Alex Denner successfully pushed for the ouster of CEO
Harvey Berger, the founder of the company.
|
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
AstraZeneca Is Buying a Majority Stake in Acerta Pharma for $4 Billion [TheStreet]
|
|
|
|
|
|
Acerta's
acalabrutinib is being tested as a treatment for various types of
leukemia, lymphoma and other cancers. The New England Journal of
Medicine recently published positive results of early clinical testing
of the drug, which is seen as a rival to Johnson & Johnson and
AbbVie's Imbruvica and as a potential blockbuster treatment.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.5 ASCO
|
|
|
|
5.6 ESMO
|
|
|
|
5.7 SABCS
|
|
|
Mastectomy vs. lumpectomy: stories needed more context [HealthNewsReview]
|
|
|
|
|
|
There’s
always room for improvement, and some outlets glossed over key
limitations, failed to address cost, and didn’t give readers a complete
portrait of the harms associated with each approach. Hopefully this
review will help journalists provide that much-needed context to stories
filed at their next conference.
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|